Wasted medicines and avoidable adverse events: a multibillion pound problem

References

• Rawlins MD and Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224–227
   PubMed Web of Science ®Google Scholar
• Greener M. Drug safety on trial. EMBO Rep 2005; 6: 202–204
   PubMed Web of Science ®Google Scholar
• McDonnell PJ and Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331–1336
   PubMed Web of Science ®Google Scholar
• Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz- Livshits T, Levy M, Brune K, Hahn EG. Readmissions and adverse drug reactions in internal medicine: the economic impact J Intern Med 2004; 255: 653–663
   Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200- 1205
   Google Scholar
• Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77–83
   PubMed Web of Science ®Google Scholar
• Seeger JD, Kong SX, Schumock GT. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy 1998; 18: 1284–1289
   Google Scholar
• Schlienger RG, Oh PI, Knowles SR, Shear NH. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl 7: S27–S32
   Google Scholar
• Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother 2003; 4: 319–326
   PubMed Web of Science ®Google Scholar
• Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34: 1373- 1379
   Google Scholar
• Lapeyre-Mestre M, Gary J, Machelard- Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997; 53: 19–22
   PubMed Web of Science ®Google Scholar
• Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol 2001; 56: 935–41
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ 2004; 329: 15–19
   Google Scholar
• Wu WK and Pantaleo N. Evaluation of outpatient adverse drug reactions leading to hospitalization. Am J Health Syst Pharm 2003; 60: 253–259
   PubMed Web of Science ®Google Scholar
• Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–167
   PubMed Web of Science ®Google Scholar
• Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996; 44: 194–197
   PubMed Web of Science ®Google Scholar
• Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47: 209–216
   Google Scholar
• Livingston S. The Older patient Pharmaceutical Journal 2004: 272: 862–863
   Google Scholar
• Swedberg K, Cleland J, Dargie H. et al Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 2005; 26: 1115–1140
   Google Scholar
• Wilkinson T and de Picciotto J. Swallowing problems in the normal ageing population. S Afr J Commun Disord 1999; 46: 55–64
   Google Scholar
• Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Community Dent Oral Epidemiol 1996; 24: 312–316
   PubMed Web of Science ®Google Scholar
• Gilbert GH, Heft MW, Duncan RP. Mouth dryness as reported by older Floridians Community Dent Oral Epidemiol 1993; 21: 390–397
   PubMedGoogle Scholar
• Wright D. Medication administration in nursing homes. Nurs Stand 2002; 16: 33–38
   PubMedGoogle Scholar
• Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003; 1(4 Suppl 2): 18–24
   Google Scholar
• Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731–1738
   PubMed Web of Science ®Google Scholar
• Sjoqvist F. Drug safety in relation to efficacy: the view of a clinical pharmacologist. Pharmacol Toxicol 2000; 86 Suppl 1: 30–32
   Google Scholar
• Gholami Kand Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33: 236–240
   PubMed Web of Science ®Google Scholar
• Lundkvist J and Jonsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004; 18: 275–280
   PubMed Web of Science ®Google Scholar
• Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring–cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl 3: S79–S90
   PubMedGoogle Scholar
• Thurmann PA and Schmitt K Detection and evaluation of adverse drug effects Med Klin 2000; 95: 4–8
   Google Scholar
• van Kraaij DJ, Haagsma CJ, Go IH, Gribnau FW. Drug use and adverse drug reactions in 105 elderly patients admitted to a general medical ward. Neth J Med 1994; 44: 166–173
   PubMed Web of Science ®Google Scholar
• Lagnaoui R, Moore N, Fach J, Longy- Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56: 181–186
   PubMed Web of Science ®Google Scholar
• Vila A, San Jose A, Roure C, Armadans L, Vilardell M. Prospective multicenter study of adverse drug reactions in hospitalized elderly patients. Med Clin 2003; 120: 613–618
   Google Scholar
• Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf 2002; 25: 1035–1044
   Google Scholar
• Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S, Schneider T, Levy M, Hahn E, Brune K. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26: 353–362
   PubMed Web of Science ®Google Scholar
• Tegeder I, Levy M, Muth-Selbach U, Oelkers R, Neumann F, Dormann H, Azaz- Livshits T, Criegee-Rieck M, Schneider HT, Hahn E, Brune K, Geisslinger G. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557–564
   Google Scholar
• Gonzalez-Martin G, Caroca CM and Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998; 36: 530–533
   Google Scholar
• Ryan-Woolley BM and Rees JA. Initializing concordance in frail elderly patients via a medicines organizer. Ann Pharmacother 2005; 39: 834–839
   Google Scholar
• Morgan TM. The economic impact of wasted prescription medication in an outpatient population of older adults. J Fam Pract 2001; 50: 779–781
   PubMed Web of Science ®Google Scholar
• Peterson AM, McGhan WF. Pharmacoeconomic impact of non- compliance with statins. Pharmacoeconomics 2005; 23: 13–25
   PubMed Web of Science ®Google Scholar
• Moerman D. Meaning, medicine and the ‘placebo’ effect. Cambridge University Press 2002 1st edition pp116-118
   Google Scholar
• Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia Psychiatr Serv 2003; 54: 508–516
   Google Scholar
• Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician 2005; 71: 2089–2090
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310
   PubMed Web of Science ®Google Scholar
• Riedl MA and Casillas AM. Adverse Drug Reactions: Types and Treatment Options Am Fam Physician 2003; 68: 1781–90
   Google Scholar
• Curtis L and Netten A. Unit costs of health & social care 2004. Personal Social Services Research Unit, University of Kent, Canterbury 2004.
   Google Scholar